Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Identification and Characterization of CMV-Specific, HLA-C*07:02 Restricted Antibodies

Moritz Bewarder, MD, Gerhard Held, MD, Lorenz Thurner, MD, Klaus Dieter Preuss, PhD, Gabi Carbon, Birgit Bette, Konstantinos Christofyllakis, MD, Arne Felbel, Dominic Kaddu-Mulindwa, MD, Niels Murawski, MD, Stephan Stilgenbauer, Frank Neumann, PhD

Blood (2019) 134 (Supplement_1): 5616.

https://doi.org/10.1182/blood-2019-126998

Published: 2019

Journal Articles

Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Elise A. Chong, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Nicole Winchell, Ellen Napier, NP, Anthony R. Mato, MD MSCE, J. Joseph Melenhorst, PhD, Marco Ruella, MD, Simon F Lacey, PhD BS, Carl H June, MD, Stephen J. Schuster, MD

Blood (2018) 132 (Supplement 1): 4198.

https://doi.org/10.1182/blood-2018-99-119502

Published: 2018

Journal Articles

T Cells Engineered with a Novel Chimeric Receptor Demonstrate Durable In Vivo Efficacy Against Disseminated Multiple Myeloma

Ksenia Bezverbnaya, BSc, Vivian Lau, MSc, Craig Aarts, MSc, Galina Denisova, PhD, Arya Afsahi, MSc, Carole Evelegh, BSc, Derek Cummings, BSc, Christopher Helsen, PhD, Jonathan Bramson, PhD

Blood (2018) 132 (Supplement 1): 962.

https://doi.org/10.1182/blood-2018-99-118569

Published: 2018

Journal Articles

Characterization of Interaction of Factor VIII with Engineered Variants of a Single-Chain Variable Antibody Fragment

Svetlana A Shestopal, PhD, Leonid A Parunov, PhD, Mikhail V Ovanesov, PhD, Timothy K Lee, PhD, Andrey G Sarafanov, PhD

Blood (2018) 132 (Supplement 1): 1170.

https://doi.org/10.1182/blood-2018-99-115455

Published: 2018

Journal Articles

A Novel Switchable CAR-T Platform for Acute Lymphoblastic Leukemia Treatment

Eduardo Laborda, DVM, PhD, Eric N Hampton, PhD, Sung C Lee, PhD, Ashley K Woods, PhD, Travis S Young, PhD

Blood (2017) 130 (Supplement 1): 3890.

https://doi.org/10.1182/blood.V130.Suppl_1.3890.3890

Published: 2017

Journal Articles

Phase I/II Study of Pembrolizumab for Progressive Diffuse Large B Cell Lymphoma after Anti-CD19 Directed Chimeric Antigen Receptor Modified T Cell Therapy

Elise A. Chong, MD, J. Joseph Melenhorst, PhD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Anthony R. Mato, MD, Lifeng Tian, PhD, Harit Parakandi, Simon F Lacey, PhD BS, Carl H June, MD, Stephen J. Schuster, MD

Blood (2017) 130 (Supplement 1): 4121.

https://doi.org/10.1182/blood.V130.Suppl_1.4121.4121

Published: 2017

Journal Articles

Novel Adapter Chimeric Antigen Receptor (aCAR) T Cells for Temporally Controllable Targeting of Single and Multiple Tumor Antigens

Christian M. Seitz, MD, Patrick Schlegel, MD, Jana Hau, Ann-Christin Krahl, Sarah Schroeder, Giulia Bender, Selina Reiter, Sabine Schleicher, PhD, Karin Schilbach, PhD, Martin Ebinger, MD, Philipp Knopf, MSc, Manfred Kneilling, MD, Bernd J. Pichler, PhD, Joerg Mittelstaet, PhD, Dominik Lock, MSc, Andrew Kaiser, PhD, Peter J. Lang, MD, Rupert Handgretinger, MD

Blood (2017) 130 (Supplement 1): 1912.

https://doi.org/10.1182/blood.V130.Suppl_1.1912.1912

Published: 2017

Journal Articles

An Innovative in Vitro Potency Assay Designed to Predict the Fate of Chimeric Antigen Receptors Modified T Cell Therapy Post Infusion in ALL

Junxia Wang, MD PhD, Mark Dudley, PhD, Therese Choquette, PhD, Margit Jeschke, PhD, Erik Rutjens, PhD, Sadik Kassim, PhD

Blood (2016) 128 (22): 5830.

https://doi.org/10.1182/blood.V128.22.5830.5830

Published: 2016

Journal Articles

Imaging Human Immune Cell Infiltration in a Xenograft Graft-Versus-Host Disease Model

Catharina Van Elssen, MD PhD, Mohammad Rashidian, PhD, Vladimir Vrbanac, Christian Freund, Juanjo Cragnolini, Jessica Ingram, PhD, Andrew Tager, Hidde Ploegh, PhD

Blood (2016) 128 (22): 5720.

https://doi.org/10.1182/blood.V128.22.5720.5720

Published: 2016

Journal Articles

Markers of Thromboembolic Risk Were Insignificantly Affected By Either Intraosseous or Intravenous Idarucizumab in a Dabigatran-Anticoagulated Porcine Polytrauma Model

Markus Honickel, MD, Akman Necib, MD, Hugo ten Cate, MD PhD, Rolf Rossaint, MD Prof, Oliver Grottke, MD PhD

Blood (2016) 128 (22): 2623.

https://doi.org/10.1182/blood.V128.22.2623.2623

Published: 2016

Journal Articles

Idarucizumab, a Specific Reversal Agent for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran-Induced Anticoagulation in Japanese Healthy Male Volunteers

Joanne van Ryn, PhD, Masahiro Yasaka, MD PhD, Ippei Ikushima, MD PhD, Akiko Harada, PhD, Atsushi Taniguchi, MSc, Susumu Imazu, PhD, Stephen Norris, PhD, Dietmar Gansser, PhD, Joachim Stangier, PhD

Blood (2016) 128 (22): 2627.

https://doi.org/10.1182/blood.V128.22.2627.2627

Published: 2016

Journal Articles

Minimally Ex Vivo Manipulated Gene-Modified T Cells Display Enhanced Tumor Control

Saba Ghassemi, PhD, Patel Prachi, John Scholler, Selene Nunez-Cruz, PhD, David M. Barrett, MD PhD, Felipe Bedoya, PhD, Joseph A. Fraietta, PhD, Simon Francis Lacey, PhD BS, Bruce L Levine, PhD, Stephen A. Grupp, MD PhD, Carl H June, MD, Michael C. Milone, MD PhD, J. Joseph Melenhorst, PhD

Blood (2016) 128 (22): 4549.

https://doi.org/10.1182/blood.V128.22.4549.4549

Published: 2016

Journal Articles

Coupling Therapeutics to Human Erythrocytes Demonstrates Target-Dependent Effects on Red Cell Physiology While Preserving Efficacy

Carlos Hipolito Villa, MD PhD, Daniel Pan, PhD, Ian Johnston, BS, Colin F Greineder, MD PhD, Marion E. Reid, PhD, Douglas B. Cines, MD, Mortimer Poncz, MD, Don L. Siegel, MD, PhD,, Vladimir R Muzykantov, MD PhD

Blood (2016) 128 (22): 701.

https://doi.org/10.1182/blood.V128.22.701.701

Published: 2016

Journal Articles

Von Willebrand Factor Interaction with FVIII: Development of Long Acting FVIII Therapies

Peter J Lenting, PhD, Vincent Muczynski, PhD, Gabriel Aymé, PhD, Cecile V. Denis, PhD, Olivier D. Christophe, PhD

Blood (2016) 128 (22): SCI-8.

https://doi.org/10.1182/blood.V128.22.SCI-8.SCI-8

Published: 2016

Journal Articles

Humanized Anti-PR1/HLA-A2 T Cell Receptor-like Monoclonal Antibody, h8F4, Has Multiple Effector Mechanisms

Anna Sergeeva, PhD, Hong He, MD, Kathryn Cox, Lisa St John, PhD, Mei Sang, Celine Kerros, PhD, Qiaochuan Li, PhD MD, Amanda Herrmann, Karen Clise-Dwyer, PhD, Qing Ma, PhD, Gregory Lizee, PhD, Gheath Alatrash, DO, PhD, Jeffrey J. Molldrem, MD

Blood (2016) 128 (22): 4061.

https://doi.org/10.1182/blood.V128.22.4061.4061

Published: 2016

Journal Articles

99m technetium-Tocilizumab Fragments As Molecular Imaging Agent for Multiple Myeloma

Ximena Camacho, MSc, Camila Machado, PhD, maria Fernanda Garcia, PhD, Marcelo Fernandez, PhD, Omar Alonso, Hugo Cerecetto, Roger Chammas, Juan Pablo Gambini, Pablo Cabral, PhD, Eloisa Riva, MD

Blood (2015) 126 (23): 4214.

https://doi.org/10.1182/blood.V126.23.4214.4214

Published: 2015

Journal Articles

Rviii-Singlechain Pharmacokinetics and Safety in Children Less Than 12 Years of Age

Claudia Djambas Khayat, MD BS, Oleksandra Stasyshyn, MD, Genadi Iosava, Prof., D.M., Ph. D., Jeannie B Ong, MD, Faraizah Abdul Karim, MD, Debra M. Bensen-Kennedy, MD, Katie St. Ledger, MS, Tharin Limsakun, PhD, Alex Veldman, MD, Ingrid Pabinger, MD

Blood (2015) 126 (23): 3524.

https://doi.org/10.1182/blood.V126.23.3524.3524

Published: 2015

Journal Articles

Platelet-Targeted rFVIIa-Xten Improves Thrombin Generation and Fibrin Formation Compared to Recombinant FVIIa

Maria M. Aleman, PhD, Elena N. Kistanova, Nancy Moore, Volker Schellenberger, PhD, Robert Peters, PhD, Joe Salas, PhD

Blood (2015) 126 (23): 2269.

https://doi.org/10.1182/blood.V126.23.2269.2269

Published: 2015

Journal Articles

Pre-Clinical Characterization of T Cell-Dependent Bispecific Antibody Anti-CD79b/CD3 As a Potential Therapy for B Cell Malignancies

L. Laura Sun, PhD, Xiaocheng Chen, Yvonne Chen, Mark S. Dennis, Diego Ellerman, PhD, Clarissa Johnson, Mary Mathieu, Amy Oldendorp, Andrew G. Polson, PhD, Arthur Reyes, Eric Stefanich, Hong Wang, PhD, Peiyin Wang, Bing Zheng, Allen J. Ebens, PhD

Blood (2014) 124 (21): 4507.

https://doi.org/10.1182/blood.V124.21.4507.4507

Published: 2014

Journal Articles

Construction of the Lentiviral and Electric Transfection Vectors Encoding Anti-Human CD30 or CD33 Chimeric Antigen Receptor (CAR) Gene and Respective Expression Injurkat Leukemia Cell Line

Ke Zeng, MD, Ting Niu, MD PhD

Blood (2014) 124 (21): 5950.

https://doi.org/10.1182/blood.V124.21.5950.5950

Published: 2014

NARROW

Identification and Characterization of CMV-Specific, HLA-C*07:02 Restricted Antibodies

Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

T Cells Engineered with a Novel Chimeric Receptor Demonstrate Durable In Vivo Efficacy Against Disseminated Multiple Myeloma

Characterization of Interaction of Factor VIII with Engineered Variants of a Single-Chain Variable Antibody Fragment

A Novel Switchable CAR-T Platform for Acute Lymphoblastic Leukemia Treatment

Phase I/II Study of Pembrolizumab for Progressive Diffuse Large B Cell Lymphoma after Anti-CD19 Directed Chimeric Antigen Receptor Modified T Cell Therapy

Novel Adapter Chimeric Antigen Receptor (aCAR) T Cells for Temporally Controllable Targeting of Single and Multiple Tumor Antigens

An Innovative in Vitro Potency Assay Designed to Predict the Fate of Chimeric Antigen Receptors Modified T Cell Therapy Post Infusion in ALL

Imaging Human Immune Cell Infiltration in a Xenograft Graft-Versus-Host Disease Model

Markers of Thromboembolic Risk Were Insignificantly Affected By Either Intraosseous or Intravenous Idarucizumab in a Dabigatran-Anticoagulated Porcine Polytrauma Model

Idarucizumab, a Specific Reversal Agent for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran-Induced Anticoagulation in Japanese Healthy Male Volunteers

Minimally Ex Vivo Manipulated Gene-Modified T Cells Display Enhanced Tumor Control

Coupling Therapeutics to Human Erythrocytes Demonstrates Target-Dependent Effects on Red Cell Physiology While Preserving Efficacy

Von Willebrand Factor Interaction with FVIII: Development of Long Acting FVIII Therapies

Humanized Anti-PR1/HLA-A2 T Cell Receptor-like Monoclonal Antibody, h8F4, Has Multiple Effector Mechanisms

99m technetium-Tocilizumab Fragments As Molecular Imaging Agent for Multiple Myeloma

Rviii-Singlechain Pharmacokinetics and Safety in Children Less Than 12 Years of Age

Platelet-Targeted rFVIIa-Xten Improves Thrombin Generation and Fibrin Formation Compared to Recombinant FVIIa

Pre-Clinical Characterization of T Cell-Dependent Bispecific Antibody Anti-CD79b/CD3 As a Potential Therapy for B Cell Malignancies

Construction of the Lentiviral and Electric Transfection Vectors Encoding Anti-Human CD30 or CD33 Chimeric Antigen Receptor (CAR) Gene and Respective Expression Injurkat Leukemia Cell Line

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only